Table 2. . Combination chemotherapy with immune and targeted treatments in melanoma.
| Study (author) | Treatment arms | Number per arm | ORR (CR/PR) | CRR (CR/PR/SD) | Median PFS/TTP | Median OS | Ref. |
|---|---|---|---|---|---|---|---|
| Phase III, DTIC ± ipilumumab (Robert et al.) | DTIC plus placebo | 252 | 10.3% | 30.1% | – | 9.1 months | [38] |
| DTIC plus ipilumumab | 250 | 15.2% | 33.2% | – | 11.2 months | ||
| Phase II, fotemustine and ipilumumab (Di Giacomo et al.) | Ipilumumab and fotemustine | 86 | 29.1% | 46.5% | 5.3 months | 13.3 months | [39] |
| Phase II, sorafenib plus DTIC (McDermott et al.) | DTIC plus placebo | 50 | 12% | – | 11.7 weeks | – | [40] |
| DTIC plus sorafenib | 51 | 24% | – | 21.1 weeks | – | ||
| Phase III, sorafenib plus CP (Hauschild et al.) | CP plus placebo | 135 | 11% | 62% | 17.9 weeks | 42 weeks | [33] |
| CP plus sorafenib | 135 | 12% | 66% | 17.4 weeks | 42 weeks | ||
| Phase III, sorafenib plus DTIC (Flaherty et al.) | CP plus placebo | 413 | 18.2% | 56.9% | 4.9 months | 11.3 months | [34] |
| CP plus sorafenib | 410 | 20.5% | 61% | 4.2 months | 11.1 months | ||
| Phase II, DTIC plus selumetinib or placebo (Robert et al.) | DTIC plus placebo | 46 | 40%† | 69% | 3.0 months | 10.5 months | [41] |
| DTIC plus selumetinib | 45 | 26%† | 48% | 5.6 months | 13.9 months | ||
| DOC-MEK study, docetaxel plus placebo or selumetinib (Gupta et al.) | Docetaxel plus placebo | – | 14% | – | – | – | [42] |
| Docetaxel plus selumetinib | – | 32% | – | – | – | ||
| BEAM study, CP plus placebo or bevacizumab (Kim et al.) | CP plus placebo | 71 | 16.4% | – | 4.2 months | 9.2 months‡ | [43] |
| CP plus bevacizumab | 143 | 25.5% | – | 5.6 months | 12.3 months | ||
†Unconfirmed.
‡At 17 months of follow-up.
CP: Carboplatin/paclitaxel; CRR: Clinical response rate; DTIC: Dimethyl triazeno imidazole carboxamide; ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival; PR: Partial response; SD: Stable disease; TTP: Time to progression.